353 related articles for article (PubMed ID: 28556418)
1. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis.
Papp KA; Gooderham MJ; Girard G; Raman M; Strout V
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):1324-1332. PubMed ID: 28556418
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis.
Nakagawa H; Iizuka H; Nemoto O; Shimabe M; Furukawa Y; Kikuta N; Ootaki K
J Dermatol Sci; 2020 Aug; 99(2):82-89. PubMed ID: 32651105
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
Nemoto O; Hirose K; Shibata S; Li K; Kubo H
Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
[TBL] [Abstract][Full Text] [Related]
4. First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis.
Gottlieb AB; Krueger JG; Sandberg Lundblad M; Göthberg M; Skolnick BE
PLoS One; 2015; 10(8):e0134703. PubMed ID: 26252485
[TBL] [Abstract][Full Text] [Related]
5. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.
Gottlieb AB; Miller B; Lowe N; Shapiro W; Hudson C; Bright R; Ling M; Magee A; McCall CO; Rist T; Dummer W; Walicke P; Bauer RJ; White M; Garovoy M
J Cutan Med Surg; 2003; 7(3):198-207. PubMed ID: 12717587
[TBL] [Abstract][Full Text] [Related]
7. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis.
Kierkus J; Pesegova M; Klopocka M; Brankovic M; Kasai N; Efuni S; Kong J; Nakajima Y; Jordan C; Matsui T; Feagan BG; Strout V
Crohns Colitis 360; 2020 Jul; 2(3):otaa049. PubMed ID: 36776497
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis.
Svecova D; Lubell MW; Casset-Semanaz F; Mackenzie H; Grenningloh R; Krueger JG
J Am Acad Dermatol; 2019 Jul; 81(1):196-203. PubMed ID: 30926369
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.
Khalilieh S; Hodsman P; Xu C; Tzontcheva A; Glasgow S; Montgomery D
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):294-300. PubMed ID: 29510001
[TBL] [Abstract][Full Text] [Related]
12. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Papp KA; Bressinck R; Fretzin S; Goffe B; Kempers S; Gordon KB; Caro I; Walicke PA; Wang X; Menter A;
Int J Dermatol; 2006 May; 45(5):605-14. PubMed ID: 16700803
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis.
Furihata K; Ishiguro Y; Yoshimura N; Ito H; Katsushima S; Kaneko E; Shimabe M; Mukai M; Watanabe R; Morishige T
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):870-883. PubMed ID: 33512065
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
16. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
Papp KA; Leonardi C; Menter A; Ortonne JP; Krueger JG; Kricorian G; Aras G; Li J; Russell CB; Thompson EH; Baumgartner S
N Engl J Med; 2012 Mar; 366(13):1181-9. PubMed ID: 22455412
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.
Langley RG; Papp K; Bissonnette R; Toth D; Matheson R; Hultquist M; White B
Int J Dermatol; 2010 Jul; 49(7):818-28. PubMed ID: 20618506
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
20. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis.
Gottlieb AB; Cooper KD; McCormick TS; Toichi E; Everitt DE; Frederick B; Zhu Y; Pendley CE; Graham MA; Mascelli MA
Curr Med Res Opin; 2007 May; 23(5):1081-92. PubMed ID: 17519075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
